Theratechnologies Showcases Key Poster Presentations at IDWeek
Exciting Developments from Theratechnologies at IDWeek 2024
Theratechnologies Inc. is gearing up to share groundbreaking insights at the upcoming IDWeek 2024 event, a prestigious gathering focused on infectious diseases. This year's conference will take place from October 16 to 19 in Los Angeles, providing an excellent platform for professionals in the HIV field to exchange valuable information.
Innovative Research Highlighted in Poster Presentations
At IDWeek, Theratechnologies will showcase three significant poster presentations, each targeting crucial aspects of HIV treatment and management. The featured research dives into the correlation between excess visceral abdominal fat (EVAF) and cardiovascular risks in individuals living with HIV. Identifying this link is critical as it guides healthcare providers in optimizing treatment plans.
Importance of Managing Cardiovascular Risks
The first captivating poster will discuss how utilizing tesamorelin, a growth hormone-releasing factor (GHRF) analog, can effectively reduce EVAF and, consequently, cardiovascular risk among people with HIV. Given the increasing lifespan of individuals diagnosed with HIV, understanding the interplay between body fat and heart health is imperative.
The potential for tesamorelin to reduce these risks may pave the way for innovative treatment strategies, providing individuals with a better quality of life. Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer of Theratechnologies, asserts that as patients live longer, they face new challenges associated with long-term medication exposure. By bringing these issues to light at IDWeek, Theratechnologies aims to enrich the conversation surrounding HIV treatment.
PROMISE-US Trial Insights
The second poster will focus on the study design and baseline characteristics of the PROMISE-US trial, which evaluates the outcomes of heavily treatment-experienced patients with multidrug resistance being treated with ibalizumab, a CD4-directed post-attachment inhibitor of HIV. This observational study aims to fill gaps in knowledge surrounding real-world data for underserved populations, which is crucial for developing effective therapies.
Details About Theratechnologies' Presentations
Theratechnologies has prepared the following presentations for attendees:
Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
Lead Author: Steven Grinspoon, MD, Massachusetts General Hospital and Harvard Medical School
Date & Time: Thursday, October 17, 2024, 12:15 PM – 1:30 PM PT
Session Title: HIV: Complications and Coinfections
Location: Halls JK
Poster Board Number: P-433
Cardiovascular Risk Scores and Insulin Resistance are Higher with Excess Visceral Abdominal Fat in People with HIV in the Modern Antiretroviral (ART) Era
Presenting Author: Karam Mounzer, MD, University of Pennsylvania Perelman School of Medicine
Date & Time: Thursday, October 17, 2024, 12:15 PM – 1:30 PM PT
Session Title: HIV: Complications and Coinfections
Location: Halls JK
Poster Board Number: P-453
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
Presenting Author: Dr. Charlotte-Paige Rolle, M.D., Orlando Immunology Center and Emory Rollins School of Public Health
Date & Time: Thursday, October 17, 2024, 12:15 PM – 1:30 PM PT
Session Title: HIV: Treatment
Location: Halls JK
Poster Board Number: P-565
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is dedicated to advancing innovative biopharmaceutical therapies that address critical medical needs. Their focus on research and development manifests in their commitment to improving the lives of individuals living with chronic conditions. For more information about Theratechnologies and their offerings, visit their website at www.theratech.com.
Frequently Asked Questions
What is IDWeek 2024?
IDWeek 2024 is a prominent conference that brings together healthcare professionals to discuss the latest advancements in infectious disease research and treatment.
What will Theratechnologies present at IDWeek?
Theratechnologies will present three important posters focusing on cardiovascular risks associated with HIV and findings from their PROMISE-US trial.
Who are the lead authors of the studies being presented?
The studies will feature experts such as Steven Grinspoon, Karam Mounzer, and Dr. Charlotte-Paige Rolle as lead authors.
When will the presentations take place?
The presentations will be held on Thursday, October 17, 2024, from 12:15 PM to 1:30 PM PT.
How does Theratechnologies contribute to the field of HIV treatment?
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.